核苷（酸）类抗病毒药物对失代偿期乙型肝炎肝硬化患者肾功能的影响研究*

doi:10.3969/j.issn.1672-5069.2015.05.005

实用肝脏病杂志 ›› 2015, Vol. 18 ›› Issue (5): 463-467.doi: 10.3969/j.issn.1672-5069.2015.05.005

核苷（酸）类抗病毒药物对失代偿期乙型肝炎肝硬化患者肾功能的影响研究^*

曾阿娟，范春蕾，李磊，张鑫，赵文敏，郑俊福，王征，董培玲，丁惠国

100069 北京市首都医科大学附属北京佑安医院肝病消化中心/重大传染病防治协同创新中心

收稿日期:2015-06-30 出版日期:2015-09-10 发布日期:2016-02-18
通讯作者: 丁惠国，E-mail:dinghuiguo@ccmu.edu.cn E-mail:mmfan@163.com
作者简介:曾阿娟，女，27岁，医学硕士，住院医师。主要从事慢性肝病的临床研究。E-mail: zengajuan1987@163.com;范春蕾，女，42岁，医学博士，副主任医师，副教授。主要从事肝病的防治研究。E-mail: mmfan@163.com
基金资助:
国家十二五重大传染病专项（2012ZX10002-008-05）；首都发展基金专项（2014-1-2181)

Effects of nucleos（t）ide analogues on renal functions in patients with Hepatitis B virus-induced decompensated liver cirrhosis

Zeng Ajuan,Fan Chunlei，Li，Lei，et al.

Department of Gastroenterology and Hepatology， You’an Hospital Affiliated to Capital Medical University，Beijing 100069

Received:2015-06-30 Online:2015-09-10 Published:2016-02-18

摘要/Abstract

摘要： 目的评价核苷（酸）类药物（NUCs）对失代偿期乙型肝炎肝硬化患者肾功能的影响。方法纳入失代偿期乙型肝炎肝硬化患者306例，其中接受抗病毒治疗者中包括拉米夫定（LAM）治疗者39例、阿德福韦（ADV） 73例、替比夫定（LDT）34例、恩替卡韦（ETV） 48例、LAM联合ADV 41例、LDT联合ADV 25例和未抗病毒治疗对照46例。随访3年。排除失访、随访时间小于3年和对照组中途开始抗病毒治疗者97例，最终209例患者纳入本研究。观察估算的肾小球滤过率（eGFR）、血清肌酐和尿素氮水平变化。结果与对照组比，各抗病毒治疗组1年、2年、3年时eGFR较基线均无明显变化（P>0.05），而LDT、LDT联合ADV组eGFR有逐年升高趋势（P>0.05）；本组失代偿期乙型肝炎肝硬化患者在基线时存在轻度肾功能损害者58例（27.8%）；在存在轻度肾损伤（基线eGFR<90 ml?min-1?1.73m-2）的患者，经LDT或LDT联合ADV治疗3年时患者eGFR复常率分别为55.6%和50%；各组患者血清肌酐和尿素氮水平与基线比无显著性差异（P>0.05）。结论 LDT单药或联合ADV可改善失代偿期乙型肝炎肝硬化患者的肾功能。

关键词: 肝硬化, 失代偿期, 乙型肝炎, 核苷（酸）类似物, 肾损害

Abstract: Objective To evaluate the effect of nucleos（t）ide analogues （NUCs） on renal functions in patients with hepatitis B virus（HBV）-induced decompensated liver cirrhosis. Methods In this cohort study，306 patients with HBV-associated decompensated cirrhosis were assigned to receive lamivudine（LAM，n=39），adefovir （ADV，n=73），telbivudine （LDT，n=34），entecavir （ETV，n=48），LDT and ADV （n=41） or LAM and ADV（n=25） treatment for three years，and 46 patients didn’t receive antiviral therapy for control. 97 patients were excluded because of loss，followed-up less than three years，or those in control at baseline received antiviral therapy. 209 patients were followed-up every 3 to 6 months. Changes of estimated glomerular filtration rate （eGFR），serum creatinine and urea nitrogen were analyzed. Results Among patients who received antiviral therapy，eGFR levels did not change significantly from baseline（P>0.05），but patients who received LDT or LDT and ADV combination therapy showed gradual increase in eGFR（P>0.05）；58 patients （27.8%） had mild kidney function injuries at baseline，and the normalization rates of eGFR in patients with mild renal decrease （eGFR<90 ml?min-1?1.73 m-2） at baseline were 55.6% and 50%，respectively in patients who were treated with LDT or LDT and ADV combination；The serum creatinine and urea nitrogen levels did not obviously change in all patients. Conclusion LDT monotherapy or in combination with ADV is associated with improved renal function in patients with HBV-associated decompensated cirrhosis.

Key words: Liver cirrhosis, Decompensated, Hepatitis B, Nucleos（t）ide analogues, Kidney injury

曾阿娟，范春蕾，李磊，张鑫，赵文敏，郑俊福，王征，董培玲，丁惠国. 核苷（酸）类抗病毒药物对失代偿期乙型肝炎肝硬化患者肾功能的影响研究^*[J]. 实用肝脏病杂志, 2015, 18(5): 463-467.

Zeng Ajuan,Fan Chunlei，Li，Lei，et al.. Effects of nucleos（t）ide analogues on renal functions in patients with Hepatitis B virus-induced decompensated liver cirrhosis[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(5): 463-467.

参考文献

[1] Lok AS，McMahon BJ.Chronic hepatitis B:update 2009. Hepatology，2009，50（3）:661-662.
[2] Tanaka M，Katayama F，Kato H，et al. Hepatitis B and C virus infection and hepatocellular carcinoma in China:a review of epidemiology and control measures. J Epidemiol，2011，21（6）:401-416.
[3] Belcher JM，Garcia-Tsao G，Sanyal AJ，et al. Association of AKI with mortality and complications in hospitalized patients with cirrhosis. Hepatology，2013，57（2）:753-362.
[4] Fink SA，Jacobson IM. Managing patients with hepatitis B-related or hepatitis C-related decompensated cirrhosis. Nat Rev Gastroenterol Hepatol，2011，8（5）:285-295.
[5] Zhang QQ，An X，Liu YH，et al. Long-term nucleos（t）ide analogues therapy for adults with chronic hepatitis B reduces the risk of long-term complications: a meta-analysis. Virol J，2011，15（8）:72.
[6] 中华医学会肝病学分会和感染病学分会. 慢性乙型肝炎防治指南（2010年版）. 实用肝脏病学杂志，2011，14（2）:81-89.
[7] Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology，2009，49（Suppl 5）:S185-195.
[8] Lee M，Oh S，Lee HJ，et al. Telbivudine protects renal function in patients with chronic hepatitis B infection in conjunction with adefovir-based combination therapy. J Viral Hepat，2014，21（12）:873-881.
[9] Gane EJ，Deray G，Liaw YF，et al. Telbivudine improves renal function in patients with chronic hepatitis B. Gastroenterology， 2014，146（1）:138-146.
[10] 李小溪，钟春秀，杨淑玲，等. 阿德福韦酯和替比夫定单药治疗慢性乙型肝炎对肾脏功能影响的比较. 南方医科大学学报，2012，32（6）:826-829.
[11] Levey AS，Coresh J，Greene T，et al. Expressing the modification of Diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem，2007，53（4）:766-772.
[12] Castro AF，Coresh J. CKD surveillance using laboratory date from the population-based National Health and Nutrition Examination Survey. Am J Kidney Dis， 2009，53（3 suppl）:S46-55.
[13] 科技部十二五重大专项联合课题组专家. 乙型肝炎病毒相关肝硬化的临床诊断、评估和抗病毒治疗的综合管理. 实用肝脏病学杂志，2014，17（2）:I-X.
[14] Mallet V，Schwarzinger M，Vallet-Pichard A，et al. Effect of nucleoside and nucleotide analogues on renal function in patients with chronic hepatitis B virus monoinfection. Clin Gastroenterol Hepatol，2015，13（6）:1181-1188.
[15] Tsai MC，Chen CH，Tseng PL，et al. Comparison of renal safety and efficacy of telbivudine，entecavir and tenofovir treatment in chronic hepatitis B patient:real world experience. Clin Microbiol Infect，2015 Jun 5. [Epub ahead of print].
[16] Yapali S，Lok AS. Potential benefit of telbivudine on renal function does not outweigh its high rate of antiviral drug resistance and other adverse effects. Gastroenterology，2014，146（1）:15-19.
[17] Mauss S，Berger F，Filmann N，et al. Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B. J Hepatol，2011，55（6）:1235-1240.
[18] Ha NB，Ha NB，Garcia RT，et al. Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil. Hepatology， 2009，50（3）:727-734.
[19] Chan HL，Chen YC，Gane EJ，et al. Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naive patients with HBV-related decompensated cirrhosis. J Viral Hepat， 2012，19（10）:732-743.
[20] Qi X，Wang JY，Mao RC，et al. Impact of nucleos（t）ide analogues on the estimated glomerular filtration rate in patients with chronic hepatitis B:a prospective cohort study in China. J Viral Hepat，2015，22（1）:46-54.

核苷（酸）类抗病毒药物对失代偿期乙型肝炎肝硬化患者肾功能的影响研究^*

Effects of nucleos（t）ide analogues on renal functions in patients with Hepatitis B virus-induced decompensated liver cirrhosis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	庄莹, 林志辉. 肝硬化并发门静脉血栓临床表现和诊断进展[J]. 实用肝脏病杂志, 2019, 22(6): 765-767.
[2]	朱凌云, 张茂海, 崔莎莎, 张秋萍. 慢性乙型肝炎患者血清IL-12、IL-18水平和外周血单个核细胞FOXp3基因水平研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 816-819.
[3]	石莹莹, 王元喜. 替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 820-823.
[4]	闵峰, 黄文琪, 吴卫兵, 张丽, 范荣华. 慢性乙型肝炎患者血清脂肪细胞因子水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(6): 824-827.
[5]	张迎明, 申爽, 田飞, 孙园园. IFNL4和IL-28B基因多态性检测评估慢性乙型肝炎患者抗病毒治疗应答价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 828-831.
[6]	吴海义, 陈建新. 四种诊断模型诊断乙型肝炎病毒携带者肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 832-835.
[7]	马丽英, 沈利娟. 妊娠后期应用替诺福韦治疗血清HBV高载量孕妇阻断HBV母婴传播的疗效及安全性分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 836-839.
[8]	杨才勇, 陈娜, 李奎, 江自成, 卜蓉蓉. 慢性丙型肝炎和丙型肝炎肝硬化患者外周血Treg和Th17水平变化临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(6): 868-871.
[9]	朱娅鸽, 刘锦峰. 丁二磺酸腺苷蛋氨酸联合复方甘草酸苷治疗酒精性肝硬化患者疗效及其对血清BGP水平的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 872-875.
[10]	武丹, 马向鹰. 非酒精性脂肪性肝病肝硬化患者胰岛素抵抗水平与颈动脉硬化程度和左心室功能研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 876-879.
[11]	陈梅梅, 段晓燕, 曹海霞, 丁雯瑾. 复方鳖甲软肝片治疗原发性胆汁性肝硬化患者疗效分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 880-883.
[12]	刘李, 杨烈, 陈海洋, 何承俊, 王建宇, 陈廷昊. 肝硬化门静脉高压症并发脾动脉盗血综合征患者脾切除联合贲门周围血管离断术后门脉血流动力学的变化^*[J]. 实用肝脏病杂志, 2019, 22(6): 884-887.
[13]	何志安, 余丽萍, 赖江琼, 黄思付. ARFI评估肝硬化并发食管胃底静脉曲张患者出血和门静脉血栓的价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 888-891.
[14]	李传杰, 徐静, 王亮亮, 潘劲劲, 刘波. 恩替卡韦治疗慢性乙型肝炎患者血清HBsAg变化与病毒学应答的相关性研究[J]. 实用肝脏病杂志, 2019, 22(6): 928-929.
[15]	杜科业, 杨东亮, 刘嘉. 慢性乙型肝炎与调节性T细胞研究进展^*[J]. 实用肝脏病杂志, 2019, 22(5): 613-616.